Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Wesolowski

Showing results (121-130 of 136) with videos related to

Pageof 14
Sort By:
Cancer Research|February 17, 2016
Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib TreatmentAndrew Stiff, Prashant Trikha, Robert Wesolowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 25, 2018
Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell FunctionAndrew Stiff, Prashant Trikha, Bethany Mundy-Bosse, et al.
Breast Cancer Research and Treatment|December 7, 2024
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancerVishnu Prasath, Hinda Boutrid, Robert Wesolowski, et al.
Cancers|September 9, 2023
Depression, Inflammation, and Intestinal Permeability: Associations with Subjective and Objective Cognitive Functioning throughout Breast Cancer SurvivorshipAnnelise A Madison, Rebecca Andridge, Anthony H Kantaras, et al.
BMC Cancer|May 8, 2020
Metastatic breast cancer patient perceptions of somatic tumor genomic testingElizabeth J Adams, Sarah Asad, Raquel Reinbolt, et al.
JCO Precision Oncology|September 14, 2020
Prospective Decision Analysis Study of Clinical Genomic Testing in Metastatic Breast Cancer: Impact on Outcomes and Patient PerceptionsDaniel G Stover, Raquel E Reinbolt, Elizabeth J Adams, et al.
JAMA|May 24, 2022
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical TrialPamela J Goodwin, Bingshu E Chen, Karen A Gelmon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2026
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast CancerSara A Hurvitz, Rachel M Layman, Giuseppe Curigliano, et al.
The Journal of Clinical Investigation|August 5, 2025
BRD4 inhibition leads to MDSC apoptosis and enhances checkpoint blockade therapyHimanshu Savardekar, Andrew Stiff, Alvin Liu, et al.
The Oncologist|May 27, 2020
Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker StudyRobert Wesolowski, Daniel G Stover, Maryam B Lustberg, et al.
Pageof 14

Showing results (121-130 of 136) with videos related to

Sort By:
Pageof 14
Cancer Research|February 17, 2016
Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib TreatmentAndrew Stiff, Prashant Trikha, Robert Wesolowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 25, 2018
Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell FunctionAndrew Stiff, Prashant Trikha, Bethany Mundy-Bosse, et al.
Breast Cancer Research and Treatment|December 7, 2024
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancerVishnu Prasath, Hinda Boutrid, Robert Wesolowski, et al.
Cancers|September 9, 2023
Depression, Inflammation, and Intestinal Permeability: Associations with Subjective and Objective Cognitive Functioning throughout Breast Cancer SurvivorshipAnnelise A Madison, Rebecca Andridge, Anthony H Kantaras, et al.
BMC Cancer|May 8, 2020
Metastatic breast cancer patient perceptions of somatic tumor genomic testingElizabeth J Adams, Sarah Asad, Raquel Reinbolt, et al.
JCO Precision Oncology|September 14, 2020
Prospective Decision Analysis Study of Clinical Genomic Testing in Metastatic Breast Cancer: Impact on Outcomes and Patient PerceptionsDaniel G Stover, Raquel E Reinbolt, Elizabeth J Adams, et al.
JAMA|May 24, 2022
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical TrialPamela J Goodwin, Bingshu E Chen, Karen A Gelmon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2026
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast CancerSara A Hurvitz, Rachel M Layman, Giuseppe Curigliano, et al.
The Journal of Clinical Investigation|August 5, 2025
BRD4 inhibition leads to MDSC apoptosis and enhances checkpoint blockade therapyHimanshu Savardekar, Andrew Stiff, Alvin Liu, et al.
The Oncologist|May 27, 2020
Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker StudyRobert Wesolowski, Daniel G Stover, Maryam B Lustberg, et al.
Pageof 14